Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223
Uro-Oncology
Related content
Uro-Oncology
Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial.
Eur J Cancer.
Parker C, Zhan L, Cislo P, Reuning-Scherer J, Vogelzang NJ, Nilsson S, Sartor O, O'Sullivan JM, Coleman RE
doi: 10.1016/j.ejca.2016.10.020.
COMMENTED
Uro-Oncology
Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study
★ 2
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
★ 3
Recommended by
Alexander Meisel, Faculty Member
Eur Urol.
Thiery-Vuillemin A, Hvid Poulsen M, Lagneau E, Ploussard G, Birtle A, Dourthe LM, Beal-Ardisson D, Pintus E, Trepiakas R, Lefresne F, Lukac M, Van Sanden S, Pissart G, Reid A, AQUARiUS Investigators.
doi: 10.1016/j.eururo.2019.09.019.
Erectile and Sexual Functions and DysfunctionsUrinary IncontinenceUro-Oncology
Long-term quality of life after definitive treatment for prostate cancer: patient-reported outcomes in the second posttreatment decade
Cancer Med.
Jang JW, Drumm MR, Efstathiou JA, Paly JJ, Niemierko A, Ancukiewicz M, Talcott JA, Clark JA, Zietman AL
doi: 10.1002/cam4.1103.
Endometriosis
Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: Analysis of 2 phase III clinical trials
Am J Obstet Gynecol.
Pokrzywinski RM, Soliman AM, Chen J, Snabes MC, Coyne KS, Surrey ES, Taylor HS
doi: 10.1016/j.ajog.2019.11.1255.
Uro-Oncology
Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data
Prostate Cancer Prostatic Dis
Martini A, Parikh AB, Sfakianos JP, Montorsi F, Galsky MD, Oh WK, Tsao CK
doi: 10.1038/s41391-021-00326-3
Uro-Oncology
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study
J Clin Oncol
Chi KN, Chowdhury S, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez A, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Brookman-May S, Mundle SD, McCarthy SA, Larsen JS, Sun W, Bevans KB, Zhang K, Bandyopadhyay N, Agarwal N
doi: 10.1200/JCO.20.03488
Uro-Oncology
Response assessment using [68Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer
Prostate.
Grubmüller B, Rasul S, Baltzer P, Fajkovic H, D'Andrea D, Berndl F, Maj-Hes A, Grubmüller KH, Mitterhauser M, Wadsak W, Pfaff S, Shariat SF, Hacker M, Kramer G, Hartenbach M
doi: 10.1002/pros.23919.
Uro-Oncology
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial
Eur Urol
Baciarello G, Delva R, Gravis G, Tazi Y, Beuzeboc P, Gross-Goupil M, Bompas E, Joly F, Greilsamer C, Hon TNT, Barthelemy P, Culine S, Berdah JF, Deblock M, Ratta R, Flechon A, Cheneau C, Maillard A, Martineau G, Borget I, Fizazi K, Groupe d’Etude des Tumeurs Uro-Genitales (GETUG).
doi: 10.1016/j.eururo.2021.10.016
Uro-Oncology
Health-Related Quality of Life of Patients with Bladder Cancer in the RAZOR Trial - A Multi-Institutional Randomized Trial Comparing Robot versus Open Radical Cystectomy
J Urol.
Becerra MF, Venkatramani V, Reis IM, Soodana-Prakash N, Punnen S, Gonzalgo ML, Raolji S, Castle EP, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DA, Quek ML, Dash A, Parekh DJ
doi: 10.1097/JU.0000000000001029.